Krystal Biotech Inc Asset Resilience Ratio
Krystal Biotech Inc asset resilience ratio. Krystal Biotech Inc (KRYS) has an Asset Resilience Ratio of 27.85% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Krystal Biotech Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Krystal Biotech Inc (2017–2025)
Asset resilience ratio of Krystal Biotech Inc from 2017 to 2025. This chart shows how Krystal Biotech Inc's Asset Resilience Ratio has changed over time. Read Krystal Biotech Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Krystal Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see KRYS current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $417.89 Million | 27.85% |
| Total Liquid Assets | $417.89 Million | 27.85% |
Asset Resilience Insights
- Very High Liquidity: Krystal Biotech Inc maintains exceptional liquid asset reserves at 27.85% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Krystal Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Krystal Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Krystal Biotech Inc Asset Resilience Ratio by Year (2017–2025)
Krystal Biotech Inc asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Krystal Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.85% | $331.49 Million | $1.33 Billion | +0.92pp |
| 2024-12-31 | 23.93% | $252.65 Million | $1.06 Billion | +2.69pp |
| 2023-12-31 | 21.24% | $173.85 Million | $818.36 Million | -17.66pp |
| 2022-12-31 | 38.91% | $217.27 Million | $558.45 Million | +23.44pp |
| 2021-12-31 | 15.46% | $96.85 Million | $626.29 Million | +14.50pp |
| 2020-12-31 | 0.96% | $2.99 Million | $310.84 Million | -1.99pp |
| 2019-12-31 | 2.95% | $6.17 Million | $209.02 Million | -4.02pp |
| 2018-12-31 | 6.97% | $8.09 Million | $116.12 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $50.11 Million | -- |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystro… Read more